Messoud Ashina, Dimos D Mitsikostas, Faisal Mohammad Amin, Pinar Kokturk, Christoph J Schankin, Gurdal Sahin, Patricia Pozo-Rosich, Paul J Dorman, Tomáš Nežádal, Anne Christine Poole, Isabel Pavão Martins, Marja-Liisa Sumelahti, Verena Ramirez Campos, Andrew H Ahn, Leonidas Lyras, Cristina Tassorelli
BACKGROUND: The ongoing Pan-European Real Life (PEARL) phase 4 study is evaluating fremanezumab effectiveness and safety for the prevention of episodic and chronic migraine. This interim analysis reports primary, secondary and exploratory endpoints from when 500 participants completed at least six months of treatment. METHODS: Adults with episodic migraine or chronic migraine maintaining daily headache diaries were enrolled upon initiation of fremanezumab. Primary endpoint: proportion of participants with ≥50% reduction in monthly migraine days during the six-month period after fremanezumab initiation...
November 2023: Cephalalgia: An International Journal of Headache